| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Infliximab (TNF-alpha neutralizing antibody); the peptide is a unique proteotypic surrogate sequence derived from infliximab, enabling selective quantification. DSTYSLSSTLTLSK does not bind to biological targets.
|
|---|---|
| ln Vitro |
Not applicable; DSTYSLSSTLTLSK TFA does not possess direct enzymatic or receptor-binding activity. It serves as an analytical standard. As a surrogate peptide, it behaves identically to the corresponding tryptic peptide released from infliximab during LC-MS/MS sample preparation.
|
| ln Vivo |
Not applicable; DSTYSLSSTLTLSK TFA is not administered to animals or humans. It is used exclusively as an internal standard in analytical workflows for quantifying infliximab concentrations in plasma or serum samples.
|
| Enzyme Assay |
Not applicable; the peptide is not evaluated in enzyme/receptor binding assays. It is used in LC-MS/MS method development: the peptide (1-1000 ng/mL) is spiked into blank plasma; samples undergo protein precipitation, reduction, alkylation, and tryptic digestion; multiple reaction monitoring (MRM) transitions are optimized.
|
| Cell Assay |
Not applicable; the peptide is not used in cell-based assays. For bioanalytical protocols, the surrogate peptide is spiked into plasma or serum samples as a calibration standard or internal standard prior to LC-MS/MS analysis.
|
| Animal Protocol |
Infliximab is administered to animals or patients (3-10 mg/kg, IV). Plasma samples collected at various time points are digested with trypsin, releasing the surrogate peptide DSTYSLSSTLTLSK. This peptide is quantified by LC-MS/MS using DSTYSLSSTLTLSK TFA as a calibration standard.
|
| ADME/Pharmacokinetics |
Not applicable; DSTYSLSSTLTLSK TFA is an analytical standard not intended for in vivo administration. No PK properties are relevant. The peptide is stable during standard sample processing (protein precipitation, reduction, alkylation, tryptic digestion, LC-MS/MS).
|
| Toxicity/Toxicokinetics |
No toxicity; DSTYSLSSTLTLSK TFA is a synthetic peptide used as an analytical standard. Standard laboratory safety precautions are sufficient. Not for human or animal administration.
|
| References | |
| Additional Infomation |
DSTYSLSSTLTLSK TFA is a research-grade analytical standard for the bioanalysis of infliximab (Remicade, Avakine) and other TNF-alpha-targeting monoclonal antibodies. It has no clinical trial or marketing approval. For research use only.
|
| Molecular Formula |
C66H108F3N15O28
|
|---|---|
| Molecular Weight |
1616.64
|
| Related CAS # |
DSTYSLSSTLTLSK;177792-42-6
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~61.86 mM)
H2O :< 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (1.55 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6186 mL | 3.0928 mL | 6.1857 mL | |
| 5 mM | 0.1237 mL | 0.6186 mL | 1.2371 mL | |
| 10 mM | 0.0619 mL | 0.3093 mL | 0.6186 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
